Neoadjuvant Chemotherapy: What It Is, How It Works, and Who Gets It

Key Takeaways

• Neoadjuvant chemotherapy is chemotherapy given before surgery — not instead of it. The order may feel backwards, but it has become standard care for several cancers because it shrinks tumors, makes surgery less invasive, and shows your medical team in real time whether the drugs are working.
• It's most established for breast, bladder, colon, and lung cancers, though it's used for more than a dozen cancer types.
• Treatment usually runs 3 to 6 months in 2–3 week cycles, with surgery scheduled a few weeks after the final round.
• A pathologic complete response (pCR) — no cancer cells found in the tissue removed at surgery — is linked to lower recurrence risk and better long-term survival.
• The same chemotherapy drugs work the same way whether given before or after surgery. The timing doesn't reduce effectiveness, but it can change your surgical options (for example, lumpectomy instead of mastectomy).
• Waiting months for surgery while doing chemo is emotionally hard. That feeling is normal, valid, and worth talking about with your care team.

What Neoadjuvant Chemotherapy Actually Means

Most people we talk to ask the same question first: "My doctor wants me to do chemo BEFORE surgery — isn't that backwards?"

It feels backwards. The intuitive picture of cancer treatment is surgery first, then everything else to clean up afterward. So when your oncologist says they want to start with chemotherapy and operate later, your brain understandably files it under something is wrong.

Nothing is wrong. Neoadjuvant chemotherapy is simply chemotherapy given as the first step of treatment, before the main therapy — usually surgery. Your doctor might also call it preoperative chemotherapy or induction therapy. Different name, same idea.

This isn't experimental. For several common cancers, decades of clinical trials have shown that doing chemo first leads to better surgical options and equal or better long-term outcomes than the traditional surgery-first approach. The medical logic is solid, even when the order feels unfamiliar.

The rest of this guide walks you through that logic — why doctors recommend it, what it looks like for the cancer you've been diagnosed with, what your months of treatment will actually feel like, and the specific questions to bring to your next appointment.

Neoadjuvant vs. Adjuvant Chemotherapy: The Real Difference

There are two main ways chemotherapy gets used around surgery, and the names tell you the timing.

Neoadjuvant = before surgery.

Adjuvant = after surgery.

The drugs themselves are often identical. What changes is what your medical team can learn from each approach, and what surgical options stay open to you.

Here's how they compare directly:

Here's the part that surprises a lot of patients: for many cancers, large studies have shown similar long-term survival whether chemo is given before or after surgery. A meta-analysis combining results from 12 breast cancer studies found no difference in recurrence rates or overall survival between neoadjuvant and adjuvant approaches.

So why pick one over the other? The choice usually comes down to whether shrinking the tumor first would change the surgery itself — or give your team information they can't get any other way.

Why Some Doctors Recommend Chemo Before Surgery

There are five concrete reasons your oncologist might choose this path. You'll probably recognize one or two as relevant to your situation.

Shrinking the Tumor for Easier Surgery

A smaller tumor means a smaller operation. That can mean smaller incisions, more healthy tissue preserved, and a less invasive surgery overall.

The clearest example is breast cancer: a tumor that initially looked like a mastectomy candidate may shrink enough during neoadjuvant chemo that you become eligible for a lumpectomy instead. Same cancer, same drugs, very different surgery. One 2017 review found neoadjuvant chemotherapy reduced mastectomy rates by 7–13%, with even higher conversion rates in triple-negative breast cancer trials.

Turning Inoperable Cancers Into Operable Ones

Some tumors are simply too large, too invasive, or too tangled with nearby structures to remove safely at the time of diagnosis. Locally advanced disease, in medical language.

Neoadjuvant chemotherapy can downstage these tumors enough to make surgery possible — including for inflammatory breast cancer and certain non-small cell lung cancers that have spread to nearby lymph nodes. For these patients, neoadjuvant chemo isn't just preferable; it's often the only path to a curative operation.

Testing How Your Cancer Responds to the Drugs

This is the benefit your oncologist is probably most excited about, even if they didn't explain it that way.

Think of neoadjuvant chemo as a live test of drug sensitivity. Your team can watch — through imaging and physical exams — whether the drugs are actually shrinking your tumor. If yes, that's strong evidence those drugs are working against your specific cancer, and they'll likely keep using them. If no, your team can pivot to a different regimen before surgery rather than discovering the failure months down the road.

You don't get this information with adjuvant chemo, because there's no tumor left to measure once surgery is done. That's a meaningful clinical advantage.

Treating Microscopic Cancer Cells Earlier

By the time most cancers are diagnosed, microscopic cells may have already spread beyond the visible tumor — too small to show up on any scan. Systemic treatments like chemotherapy circulate through your whole body and can reach those cells wherever they are.

Starting that systemic treatment earlier, rather than waiting until after surgery and recovery, may catch those microscopic cells sooner.

Allowing Time for Other Planning

The months of neoadjuvant treatment aren't lost time. They're working time.

During those months, your team can complete genetic testing, you can meet with a fertility specialist if that matters to you, surgeons can plan a complex operation, and you can prepare emotionally and practically. For some patients, that breathing room is itself a benefit.

Neoadjuvant Chemotherapy for Breast Cancer

Breast cancer is the most studied use of neoadjuvant chemotherapy and the one most patients have heard about. It's now standard care for several specific subtypes.

You're likely a candidate if you have:

• Inflammatory breast cancer — neoadjuvant chemo is essentially always used here
• HER2-positive breast cancer, especially with larger tumors or positive lymph nodes
• Triple-negative breast cancer (TNBC), particularly Stage II or III
• A large tumor relative to your breast size, where shrinking it could allow a lumpectomy
• Cancer in the underarm (axillary) lymph nodes that needs downstaging before surgery

The treatment combinations depend heavily on your tumor's biology. Your biopsy report will list hormone receptor status (ER, PR), HER2 status, and often Ki-67 — these are biomarkers that tell your oncologist which drugs your specific cancer is most likely to respond to.

For HER2-positive cancers, neoadjuvant treatment usually combines chemotherapy with the HER2-targeted drugs trastuzumab (Herceptin) and pertuzumab (Perjeta). For triple-negative breast cancer at high risk of recurrence, the immunotherapy drug pembrolizumab (Keytruda) is now often added to the chemo regimen.

Worth knowing: Hormone receptor-negative tumors and HER2-positive tumors tend to have the highest pathologic complete response rates with neoadjuvant chemotherapy. Hormone receptor-positive (luminal A) tumors generally respond less dramatically — your team may recommend hormone therapy or surgery-first for those.

One small but important detail: when you have your biopsy, your radiologist will usually place a tiny metal marker clip in the tumor. This sounds odd but matters enormously. If your tumor shrinks completely during chemo (the best-case scenario), surgeons need that clip to find the original tumor location and remove the right tissue. The clip is removed during surgery. It causes no symptoms.

Neoadjuvant Chemotherapy for Bladder Cancer

For muscle-invasive bladder cancer — bladder cancer that has grown into the muscle wall — cisplatin-based neoadjuvant chemotherapy before bladder removal surgery (cystectomy) has become the standard of care.

The reason is simple: clinical trials have repeatedly shown a survival benefit. Patients who get neoadjuvant chemo before cystectomy live longer, on average, than patients who go straight to surgery. The improvement is meaningful enough that major guidelines now recommend it for almost everyone who can tolerate it.

The key qualifier is who can tolerate it. Cisplatin is hard on the kidneys, and many bladder cancer patients are older and have reduced kidney function. If you're not eligible for cisplatin, your team will discuss alternatives — sometimes a different chemo regimen, sometimes proceeding directly to surgery, and increasingly immunotherapy options that have changed the landscape for cisplatin-ineligible patients in recent years.

If your oncologist has recommended neoadjuvant chemo for bladder cancer, ask specifically about kidney function tests, what regimen they're proposing, and whether you'd be eligible for any clinical trials combining chemo with immunotherapy.

Neoadjuvant Chemotherapy for Colon and Lung Cancer

These two cancers use neoadjuvant chemotherapy in distinct ways worth understanding separately.

Colon and Rectal Cancer

For rectal cancer specifically, the field has shifted dramatically toward an approach called total neoadjuvant therapy (TNT) — delivering all the chemotherapy and radiation before surgery, rather than splitting it before and after.

Why the shift? Patients tolerate the full course better when they haven't just had major surgery. And in some cases, the response is so complete that select patients qualify for a "watch-and-wait" approach, avoiding rectal surgery altogether and being monitored closely instead. This is a significant change from how rectal cancer was treated even a decade ago.

For colon cancer that has spread to the liver, neoadjuvant chemotherapy before liver metastasis surgery has also become more common, helping shrink lesions and identify patients who'll benefit most from operating.

Lung Cancer

For non-small cell lung cancer (NSCLC) that has reached nearby lymph nodes, neoadjuvant chemotherapy is a common first step before attempting surgical removal. The newest development here is immunotherapy added to neoadjuvant chemo — combinations including drugs like nivolumab have meaningfully improved outcomes in recent years and are now built into many treatment plans for resectable NSCLC.

If you have lung cancer and your oncologist mentioned neoadjuvant treatment, ask specifically whether immunotherapy is part of the proposed plan, and what staging tests will be repeated before surgery to confirm the cancer is operable.

What to Expect During Treatment

Here's what the next several months will actually feel like, week by week. The unknowns are often scarier than the realities.

Before Your First Cycle

You'll have a workup before any chemo starts. That typically includes:

• A biopsy with biomarker testing (if not already done)
• Blood work and imaging (CT, MRI, or PET as relevant)
• A port placement — a small device under the skin that makes IV chemo much easier than repeated arm sticks
• A fertility consultation if you're of reproductive age and might want children later (chemo can affect fertility, and some preservation options need to happen before treatment starts)
• A dental check, since chemo can affect oral health
• Honest conversations with your team about what side-effect prevention looks like

If you're worried about eating well during treatment, see our guide on nutrition during chemo.

Inside a Treatment Cycle

A "cycle" sounds clinical. In practice it means: an infusion day, then a rest period, then it repeats.

Infusion day can take anywhere from 30 minutes to 6+ hours depending on which drugs you're getting. You'll be in a recliner, often with other patients, with a nurse monitoring throughout. Most people bring a book, a tablet, snacks, and a friend or family member.

The rest period is usually 2 or 3 weeks. Your body uses this time to recover blood counts and rebuild healthy cells. You'll typically feel worst in the first few days after infusion, gradually improving until the next round.

Most neoadjuvant chemo courses run 4 to 8 cycles total, taking 3 to 6 months. For more on how the timing breaks down, see how long chemo takes and how many rounds.

Common Side Effects and How to Handle Them

Side effects vary enormously depending on which drugs you're on, but the common ones across most regimens include:

• Fatigue — usually the most universal effect
• Nausea — modern anti-nausea drugs make this far more manageable than it used to be
• Hair loss — depends on the drug; for many neoadjuvant regimens it's likely. See our hair loss timeline for what to expect when
• Low blood counts — making you vulnerable to infection, bleeding, or anemia
• Neuropathy — tingling or numbness in fingers and toes, mostly from taxane-based drugs
• "Chemo brain" — mild concentration and memory effects

Most of these resolve in the months after treatment ends, though some — like neuropathy — can linger longer. If you're trying to keep working through treatment, our guide on working during chemotherapy has practical advice.

Imaging Checkpoints: Is It Working?

You'll have scans partway through treatment — typically MRI, CT, or ultrasound depending on your cancer type — and again before surgery to measure how much the tumor has shrunk.

These checkpoints serve two purposes. First, they confirm the chemo is working, which is reassuring after weeks of side effects when you can't see what's happening inside. Second, if the tumor isn't responding, your team can change the regimen before you've spent your entire treatment course on drugs that aren't working for your cancer.

From Final Cycle to Surgery

Surgery is usually scheduled 2 to 6 weeks after your last chemo cycle. That gap gives your blood counts time to recover and your immune system time to rebuild before an operation.

You'll have one more set of scans during that window to plan the surgery itself, based on what the cancer looks like now rather than what it looked like four months ago.

Understanding Your Response: pCR Explained

After surgery, a pathologist examines the tissue your surgeon removed. The best possible result is something called a pathologic complete response, or pCR — meaning no invasive cancer cells are found in the removed tissue at all.

Why does this matter so much? Because pCR is one of the strongest prognostic signs we have. Patients who achieve pCR after neoadjuvant chemotherapy have significantly lower rates of cancer recurrence and better long-term survival than those with residual disease.

A few honest qualifications:

• pCR doesn't guarantee a cure. It strongly suggests the cancer responded well, but cancer can still recur in some cases.
• Not achieving pCR doesn't mean treatment failed. Many patients with residual disease still do very well long-term. And we now have additional treatments specifically designed for patients with residual disease — like trastuzumab emtansine (T-DM1) for HER2-positive cancers and capecitabine for triple-negative cancers.
• pCR rates vary by cancer subtype. They're highest in HER2-positive cancers treated with combined chemo and HER2-targeted therapy, and in triple-negative breast cancer. They're typically lower in hormone receptor-positive cancers.

Your oncologist will explain what your specific pathology report means. Don't try to interpret it alone from internet research.

The Emotional Side of Waiting for Surgery

Here's the part most medical websites won't say out loud: doing chemotherapy for months while the cancer is still inside your body is psychologically brutal.

Many patients we've talked with describe an ongoing tension between trusting the plan and just wanting the tumor out, now. You can intellectually understand the medical logic and still feel that pull. Both things are true. Both things are normal.

Some patients also struggle with the dissonance of feeling sick from treatment while not being able to see the cancer shrinking. Your scans will show changes, but day to day, you mostly feel side effects without obvious progress. That's hard.

A few things that genuinely help:

• Ask your hospital about an oncology social worker. Most cancer centers have them, and most patients don't realize they're free.
• Find a cancer support group — in-person or online — specifically for people in active treatment. The shared experience matters.
• Consider a counselor who specializes in oncology if anxiety or depression are interfering with daily life. Don't wait until you're in crisis.
• Tell your oncology team how you're feeling emotionally. They have resources, and they'd genuinely rather know.

For an honest look at what comes after the treatment phase ends, see our resource on long-term side effects of cancer treatment.

If you're trying to make sense of these shifting emotions, this guide on Emotional Stages of a Cancer Diagnosis: What to Expect can help you understand why these feelings often intensify at certain points in the journey.

Questions to Ask Your Oncology Team

Bring this list — actually printed, on paper — to your next appointment. Bring someone with you to take notes. You will not remember the answers as well as you think you will.

• Why are you recommending chemotherapy before surgery rather than after, for my specific cancer?
• What chemotherapy drugs will I receive, and why this combination?
• How many cycles, and how long will the whole course take?
• How will we know if it's working? When are the imaging checkpoints?
• What does it mean for my plan if the tumor doesn't shrink as expected?
• What side effects should I expect, and which ones mean I should call you immediately?
• Will this treatment affect my fertility, and should I see a specialist before starting?
• What kind of surgery will I likely need afterward, and how does the chemo change that?
• What is my realistic chance of achieving a pathologic complete response?
• If I have residual disease after surgery, what are the next steps?
• Are there clinical trials I should consider for my cancer type?
• Who do I call after hours if I'm worried about a side effect?

For more guides on cancer treatment, side-effect management, and life during and after therapy, see our full resource library.

A Treatment Plan Built Around You

Three things are worth holding onto from everything above.

First, neoadjuvant chemotherapy isn't a delay or a downgrade. For breast, bladder, rectal, and many lung cancers, it's the most evidence-supported path forward — and often the path that gives you the best surgical options at the end.

Second, the order of treatment is chosen because it works. Doing chemo first lets your medical team see whether the drugs are working against your specific cancer, lets them adjust if they're not, and often lets you keep more of your body intact through surgery. The same drugs after surgery don't give them any of that information.

Third, your plan is yours. The right approach for someone else with the same diagnosis on paper may not be the right approach for you. Tumor biology, your overall health, your own priorities — all of these shape the plan. The questions in the previous section exist precisely so the plan reflects your situation, not a textbook.

If you've just been told you'll be doing chemo before surgery, you're not facing it alone, and you're not facing something experimental. You're following a path many thousands of patients have walked, with an approach refined over decades of careful research.

If you're looking for more structured support beyond one-on-one conversations, this guide on Cancer Support Groups: How They Help and How to Find One explains how connecting with others in a similar situation can make a real difference.

---

Medical Disclaimer: This article is for educational purposes and is not a substitute for personalized medical advice from your oncology team. Treatment decisions should always be made together with your doctors, based on your specific diagnosis, health status, and goals.